Bristol Myers Squibb (CELG-RI) Deferred Taxes (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Deferred Taxes of -$195.0 million for Q2 2026, up 55.38% year-over-year from -$125.5 million in Q2 2025, and down 221.12% quarter-over-quarter from $161.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Deferred Taxes (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Deferred Taxes for 18 consecutive years, with -$195.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Deferred Taxes rose 55.38% year-over-year to -$195.0 million; the TTM figure through Jun 2026 stood at -$785.0 million (up 37.75% YoY), while the FY2025 annual figure was -$965.0 million, up 53.81% from the prior year.
- Deferred Taxes declined to -$195.0 million in Q2 2026 per CELG-RI's latest filing, from $161.0 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $223.0 million in Q1 2025 and bottomed at -$1.3 billion in Q4 2023.
- Historically, Deferred Taxes has averaged -$506.3 million across 5 years, with a median of -$492.5 million in 2023.
- Annual changes were most pronounced in 2022 — Deferred Taxes plunged 1915.62% — and 2025, when it surged 131.36%.
- Bristol Myers Squibb's Deferred Taxes stood at -$624.0 million in 2022, then plunged by 112.66% to -$1.3 billion in 2023, then jumped by 40.39% to -$791.0 million in 2024, then soared by 50.44% to -$392.0 million in 2025, then soared by 50.26% to -$195.0 million in 2026.
- Business Quant data shows CELG-RI's Deferred Taxes at -$195.0 million in Q2 2026, $161.0 million in Q1 2026, and -$392.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -195.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -195.00 Mn |
| Mar 31, 2026 | 161.00 Mn |
| Dec 31, 2025 | -392.00 Mn |
| Sep 30, 2025 | -359.00 Mn |
| Jun 30, 2025 | -437.00 Mn |
| Mar 31, 2025 | 223.00 Mn |
| Dec 31, 2024 | -791.00 Mn |
| Sep 30, 2024 | -256.00 Mn |
| Jun 30, 2024 | -331.00 Mn |
| Mar 31, 2024 | -711.00 Mn |
| Dec 31, 2023 | -1.33 Bn |
| Sep 30, 2023 | -327.00 Mn |
| Jun 30, 2023 | -1.09 Bn |
| Mar 31, 2023 | -548.00 Mn |
| Dec 31, 2022 | -624.00 Mn |
| Sep 30, 2022 | -645.00 Mn |
| Jun 30, 2022 | -782.00 Mn |
| Mar 31, 2022 | -687.00 Mn |
| Dec 31, 2021 | -1.27 Bn |
| Sep 30, 2021 | -32.00 Mn |